City of San Antonio enacting plan to better leverage military medical assets

  The San Antonio Military Life Science Commercialization Action Plan seeks to better leverage ...

Rapamycin Holdings Treats First Humans in eRapa Clinical Trial

Featured image is of SwRI staff working in their cGMP clean room where clinical supplies of their ...


Learn to Prepare IND for Small Molecule Drugs

How does a drug development program evolve from a brilliant research idea? Join Southwest Research Institute ...
San Antonio biotech pitches NY investors at critical time
July 20, 2018

CytoBioscience CEO James Garvin was in New York recently to pitch the company and its technology to potential investors. CARLOS JAVIER SANCHEZ | SABJ

By W. Scott Bailey – Senior Reporter, San Antonio Business Journal

CytoBioscience has secured critical face time with more potential investors.

The San Antonio-based biotech’s CEO, James Garvin, was in New York this week to pitch the company’s expanding technology platform to the National Investment Bankers Association’s annual Investment Conference and to meet with potential financial backers.

The international event is a showcase for companies from various industries seeking to raise capital and boost exposure. Attendees at this year’s conference included registered investment advisers, private equity and venture capital groups, investment bankers, and specialized investment brokerages, among others.

Garvin said he was invited by CytoBioscience’s investment banker, Dani Hughes, and Divine Capital Markets’ Jim Hock, who is president of the National Investment Bankers Association, to present at the 144th conference. Garvin showcased the company’s cell-line technologies and the commercial market for its expertise and products.

Garvin believes the payoff from his presence in the Big Apple could extend beyond more capital investment interest.

“It’s always good to raise money, but I met companies there that could synergistically be interesting to us as well,” he told me. “It was a very good networking event in that respect.”

I reported in late March that CytoBioscience, which moved its headquarters from Germany to San Antonio a few years ago, had decided to merge with a subsidiary of WestMountain Co. The anticipated result is a new publicly traded company that will retain the CytoBioscience name, leadership and San Antonio headquarters.

Garvin said the move to become publicly traded will make CytoBioscience stronger and give it significantly more access to capital.

“There are far more capital markets available to a public company than a private company,” he said.

At a minimum, CytoBioscience comes away from the New York conference with more potential investors who know what the company does and where it’s headed.

“We’re getting nice exposure,” Garvin said.

Stay informed. Subscribe to BioMed SA news alerts.